How do you weigh the potential value or need for formal neuropsychological testing in patients with Alzheimer’s Disease prior to starting antiamyloid monoclonal antibody treatment?

It depends on what you mean by neuropsychological testing. Everyone who is to be considered for anti-amyloid treatment needs to have a diagnosis of MCI or Mild AD. So, to arrive at this diagnosis, some testing must be done that documents a decline from baseline. This can often be accomplished with m...